Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences.

• The 7^th Annual Wolfe Research Healthcare Conference with a fireside chat on Tuesday, Nov. 18, 2025, at 1:20 pm ET.
  
  
• The 37^th Annual Piper Sandler Healthcare Conference with a fireside chat on Tuesday, Dec. 2, 2025, at 12:00 pm ET.

The presentations will be available through live audio webcast links in the investor information section of Myriad’s website at investor.myriad.com. 

About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Investor Contact 
Matt Scalo 
(801) 584-3532 
[email protected] 

Media Contact 
Kate Schraml
(224) 875-4493
[email protected]

You May Also Be Interested In

• EliseAI and DOOR Team Up So Renters Can Tour Units and Get Maintenance Done on Their Own Schedule
• Checkr Announces New Partnership with Workday to Expand Income and Employment Verifications
• Fast-Track Permitting Is Reshaping the Gold-Antimony Development Race